Open Access

Insights into the role of the junctional region of Plasmodium falciparum dihydrofolate reductase-thymidylate synthase

  • Natpasit Chaianantakul1,
  • Rachada Sirawaraporn1 and
  • Worachart Sirawaraporn1Email author
Malaria Journal201312:91

DOI: 10.1186/1475-2875-12-91

Received: 19 December 2012

Accepted: 9 March 2013

Published: 12 March 2013

Abstract

Background

Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (pf DHFR-TS) is a well-defined target of anti-malarial drug, such as pyrimethamine and cycloguanil. Emergence of malaria parasites resistant to these drugs has been shown to be associated with point mutations of the gene coding for the target enzymes. Although the 3D-structure of P. falciparum bifunctional pf DHFR-TS has been reported previously, relatively little is known about the interactions between the pf DHFR and pf TS domains and the roles of the junctional region that links the two domains together. Therefore, a thorough understanding of the interaction of the two domains and the role of the junctional region of this target is important as the knowledge could assist the development of new effective anti-malarial drugs aimed at overcoming drug-resistant malaria.

Methods

A system was developed to investigate the interaction between pf DHFR and pf TS domains and the role of the junctional region on the activity of the recombinant pf TS. Based on the ability of co-transformed plasmids coding for pf DHFR and pf TS with truncated junctional region to complement the growth of TS-deficient Escherichia coli strain χ2913recA(DE3) on minimum media without thymidine supplementation, active pf TS mutants with minimal length of junctional region were identified. Interactions between active pf DHFR and the pf TS domains were demonstrated by using a bacterial two-hybrid system.

Results

Using TS-deficient E. coli strain χ2913recA(DE3), the authors have shown for the first time that in P. falciparum a junctional region of at least 44 amino acids or longer was necessary for the pf TS domain to be active for the synthesis of thymidylate for the cells. Truncation of the junctional region of the bifunctional pf DHFR-TS further confirmed the above results, and suggested that a critical length of the junctional peptide of pf DHFR-TS would be essential for the activity of TS to catalyze the synthesis of thymidylate.

Conclusion

The present study demonstrated the interactions between the pf DHFR and pf TS domains of the bifunctional pf DHFR-TS, and revealed that the junctional region linking the two protein domains is essential for the expression of catalytically active pf TS domain. The findings could be useful since inhibition of the pf DHFR-TS domain-domain interaction could form a basis for the development of new anti-malarial drugs based on targeting the non-active site region of this important enzyme.

Keywords

Malaria Plasmodium falciparum DHFR-TS Junctional region

Background

Malaria remains an important disease in many tropical and sub-tropical countries [1]. The disease has become a global health threat, with over one million deaths annually, mostly children in sub-Saharan Africa [2]. The emergence of malaria resistance to almost all the currently available anti-malarial drugs has highlighted an urgent need to identify new malarial targets, and develop new effective drugs to combat the drug-resistant parasites [38]. Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (pf DHFR-TS) is a well-defined target of antifolate drugs such as pyrimethamine and cycloquanil. The enzyme is responsible for the production of folates as well as thymidylate (dTMP) required for DNA synthesis [9]. Unfortunately, the emergence of anti-folate resistance has compromised the utility of the drugs and presented an urgent need to discover new drug targets and to develop novel effective drugs to combat drug-resistant parasites.

Structural studies of P. falciparum DHFR-TS revealed that the native enzyme is a homodimeric protein comprising 231 residues of DHFR domain (~27 kDa) at the N-terminus, followed by a short junctional region of 89 residues (~11 kDa) and 288 residues (~34 kDa) of the TS domain at the C-terminus of the protein [10, 11]. It has been postulated that such a bifunctional arrangement could have evolved as a mechanism for the tight coupling generation of reduced folates required for the synthesis of amino acids, purine, pyrimidine, and dTMP, a phenomenon called “substrate channelling”. Support for this hypothesis comes from the evidence of metabolic channelling of the H2folate produced in the TS-catalyzed reaction, which was found to proceed at a faster rate than the diffusion rate [12]. Data from the bifunctional DHFR-TS of Leishmania major and Toxoplasma gondii also supported the substrate channelling hypothesis [12, 13]. Nevertheless, the mechanism of substrate channelling for pf DHFR-TS remains unclear since, based on the structure of pf DHFR-TS, such a mechanism could not explain the delivery of H2folate from the pf TS domain to the active site of pf DHFR, and an electrostatic channelling mechanism was proposed as a possible alternative method [1416].

The junctional region (JR) linked between the DHFR and TS domains in parasitic protozoa reported thus far varies significantly in length depending upon the source [9, 10, 16, 17]. The long JR found in P. falciparum (89 amino acids) provides a number of interactions which facilitate contacts with the DHFR domain of the opposite half of the DHFR-TS dimer, and brings the two DHFR domains closer together. Structural alignments of DHFR-TS enzymes from Cryptosporidium hominis and P. falciparum revealed that the JR played an important role in the orientation of the DHFR domain relative to TS [17]. Therefore, inhibition of the interaction between the JR, the DHFR and TS domains could be a possible approach for the development of novel effective anti-malarial drugs [18]. The present study therefore describes an approach towards understanding the interactions between DHFR and TS domains of the bifunctional pf DHFR-TS, and the important role of JR on the activity of the TS domain. This is the first successful expression of the catalytically active pf TS domain that has JR attached at its N-terminus, as all attempts in the past to express pf TS domain failed. Through deletion of the JR, it is demonstrated that a critical length of JR is required for proper folding of the pf TS domain leading to an active molecule of pf TS. The findings highlight the importance of the JR which links DHFR and TS domains and suggest a possible alternative in exploiting the non-active site region of this important enzyme in developing new anti-malarial drugs to overcome drug-resistant parasites.

Methods

Materials

Restriction endonucleases and T4 DNA ligase were obtained from New England Biolabs, Life Technology, Inc. 2-deoxyuridylate, 5-fluoro-2- deoxyuridylate, and NADPH were from Sigma. MTX-sepharose CL-6B (~ 1 μmole/ml) [12], H2folate [19], and CH2H4folate [20] were prepared as described. Custom primer syntheses and DNA sequencing were from BioDesign Co Ltd and Genome Institute. TS-deficient Escherichia coli strain χ2913recA(DE3) was used for the genetic complementation studies to monitor the function of TS.

Construction and transformation of recombinant plasmids

The gene coding for P. falciparum DHFR (amino acids 1–228) was amplified using a template DNA from pETpf DHFR-TS [21]. The pf JRTS mutants were constructed by the PCR mutagenesis method. The PCR reaction (100 μl) is composed of 50 ng pETpf DHFR-TS as a DNA template, 25 ρmole of each primer (Table 1), 200 μM of dNTPs, 1.5 mM MgCl2, and 2.5 units of Taq DNA polymerase in 1 x reaction buffer. The PCR conditions were as follows: 1 cycle of 94°C for 3 min, then 25 cycles of 94°C for 45 sec, annealing at 45°C for 30 sec, and extension at 72°C for 1 min. This was followed by a final extension at 72°C for 5 min. Deletion mutants of bifunctional pf DHFR-TS were constructed using the whole plasmid amplification PCR approach [22] employing recombinant plasmid pET15b carrying the P. falciparum DHFR-TS(3D7) gene as a template and sets of primers as shown in Table 2. The PCR products were analysed by agarose electrophoresis, and were further purified using a Qiaquick Gel Extraction kit.
Table 1

Primers used for the construction of truncated pf JRTS mutants

Name

Length (bases)

Sequence (5′ → 3′)

Utilities and description

JRTSΔ232-235

28

AAAGAATCCC ATG G AACAAAATTGTATA

Sense strand PCR primer for the construction of pET-pf JRTSΔ232-235. Bold-face letters represent Met introduced in front of Glu236. Underlined sequence is the restriction site for Nco I.

JRTSΔ232-251

28

AAAGAATCCC ATGG AA AAGAATGATGAC

Sense strand PCR primer for the construction of pET-pf JRTSΔ232-251. Bold-face letters represent Met-Glu introduced infront of Lys252. Underlined sequence is the restriction site for Nco I.

JRTSΔ232-265

28

AAAGAATCCC ATG G AATTTTACAAAAAT

Sense strand PCR primer for the construction of pET-pf JRTSΔ232-265. Bold-face letters represent Met introduced in front of Glu266. Underlined sequence is the restriction site for Nco I.

JRTSΔ232-271

28

AAAGAATCCC ATG G ACAAATATAAAATT

Sense strand PCR primer for the construction of pET-pf JRTSΔ232-271. Bold-face letters represent Met introduced in front of Asp272. Underlined sequence is the restriction site for Nco I

JRTSΔ232-274

57

CCCCTCTAGA AATAATTTTGTTTAACTTTAAGAAGGAGATATACCATG AAAATTAAT

Sense strand PCR primer for theconstruction of pET-pf JRTSΔ232-274. Bold-face letters represent Met introduced in front of Lys275. Underlined sequence is the restriction site for Xba I

JRTSΔ232-276

57

CCCCTCTAGA AATAATTTTGTTTAACTTTAAGAAGGAGATATACCATG AATTATGAA

Sense strand PCR primer for the construction of pET-pf JRTSΔ232-276. Bold-face letters represent Met introduced in front of Asn277. Underlined sequence is the restriction site for Xba I

JRTSΔ232-277

57

CCCCTCTAGA AATAATTTTGTTTAACTTTAAGAAGGAGATATACCATG TATGAAAAT

Sense strand PCR primer to prepare construct pET-pf JRTSΔ232-277. Bold-face letters represent Met introduced in front of Tyr278. Underlined sequence is the restriction site for Xba I

JRTSΔ232-299

28

AAAGAATCCC ATG G AAGAGAAAAATAAA

Sense strand PCR primer to prepare construct pET-pf JRTSΔ232-299. Bold-face letters represent Met introduced in front of Glu300. Underlined sequence is the restriction site for Nco I

N3TS

22

ACTCATGGATCC TTAAGCAGCC

Antisense strand PCR primer for the construction of all pET-pf JRTS mutants. Underlined sequence is the restriction site for BamH I

Table 2

Primers used for construction of truncated bifunctional pf DHFR-TS

Name

Length (bases)

Sequence (5′ → 3′)

Utilities and description

Δ229-277 Sense

60

ACAACATTGGATTTTATCATTTATAAGAAA TAT GAAAATGATGATGATGATGAAGAAGAA

Sense strand PCR primer for the construction of pf DHFR-TSΔ229-277. Lys228 (italic) was followed by Tyr278(bold)

Δ229-277 Antisense

60

TTCTTCTTCATCATCATCATCATTTTCATATTTCTTATAAATGATAAAATCCAATGTTGT

Antisense strand PCR primer for the construction of pf DHFR-TSΔ229-277

Δ229-276 Sense

60

ACAACATTGGATTTTATCATTTATAAGAAA AAT TATGAAAATGATGATGATGATGAAGAA

Sense strand PCR primer for the construction of pf DHFR-TSΔ229-276. Lys228 (italic) was followed by Asn277(bold)

Δ229-276 Antisense

60

TTCTTCATCATCATCATCATTTTCATAATTTTTCTTATAAATGATAAAATCCAATGTTGT

Antisense strand PCR primer to amplify pf DHFR-TSΔ229-276

Δ229-275 Sense

60

ACAACATTGGATTTTATCATTTATAAGAAA ATT AATTATGAAAATGATGATGATGATGAA

Sense strand PCR primer for the construction of pf DHFR-TSΔ229-275. Lys228 (italic) was followed by Ile276(bold)

Δ229-275 Antisense

60

TTCATCATCATCATCATTTTCATAATTAATTTTCTTATAAATGATAAAATCCAATGTTGT

Antisense strand PCR primer to amplify pf DHFR-TSΔ229-275

Δ229-274 Sense

60

ACAACATTGGATTTTATCATTTATAAGAAA AAA ATTAATTATGAAAATGATGATGATGAT

Sense strand PCR primer for the construction of pf DHFR-TSΔ229-274. Lys228 (italic) was followed by Lys275(bold)

Δ229-274 Antisense

60

ATCATCATCATCATTTTCATAATTAATTTTTTTCTTATAAATGATAAAATCCAATGTTGT

Antisense strand PCR primer to amplify pf DHFR-TSΔ229-274

Δ229-271 Sense

60

ACAACATTGGATTTTATCATTTATAAGAAA GAC AAATATAAAATTAATTATGAAAATGAT

Sense strand PCR primer for the construction of pf DHFR-TSΔ229-271. Lys228 (italic) was followed by Asp272(bold)

Δ229-271 Antisense

60

ATCATTTTCATAATTAATTTTATATTTGTCTTTCTTATAAATGATAAAATCCAATGTTGT

Antisense strand PCR primer to amplify pf DHFR-TSΔ229-271

Δ229-265 Sense

60

ACAACATTGGATTTTATCATTTATAAGAAA GAA TTTTACAAAAATGTAGACAAATATAAA

Sense strand PCR primer for the construction of pf DHFR-TSΔ229-265. Lys228 (italic) was followed by Glu266(bold)

Δ229-265 Antisense

60

TTTATATTTGTCTACATTTTTGTAAAATTCTTTCTTATAAATGATAAAATCCAATGTTGT

Antisense strand PCR primer to amplify pf DHFR-TSΔ229-265

The amplified product was cloned into pAC28 expression plasmid [23] to express catalytically active pACpf DHFR. Likewise, sequences coding for truncated JR with the pf TS domain attached were amplified using the primers as listed in Table 1, and cloned into pET-15b to yield plasmids pET-pf JRTS232-235, pET-pf JRTS232-251, pET-pf JRTS232-265, pET-pf JRTS232-271, pET-pf JRTS232-274, pET-pf JRTS232-276, pET-pf JRTS232-277, and pET-pf JRTS232-299. These mutant pET-pf JRTS plasmids were transformed into electro-competent E. coli strain χ2913 cells by electroporation using pulses set at 1.8 kV, 400Ω, 25 μF and a pulse length of ~8-10 min. After centrifugation at 6,500 g at 4°C for 10 min and resuspending the cell pellets in 2 ml of 10% glycerol, a second electroporation was performed to transform 100 μl of the first transformed cells with ~50 ng of pAC-pf DHFR. After recovering the cells by addition of 0.9 ml of LB broth followed by vigorous shaking for 1 hour at 37°C, the cells were plated onto LB agar containing 100 μg/ml ampicillin and 30 μg/ml kanamycin. Colonies appeared on the plates after overnight incubation at 37°C were individually picked and grown overnight in 1 ml LB broth containing 100 μg/ml ampicillin and 30 μg/ml kanamycin at 37°C.

Truncation of JR of the bifunctional pf DHFR-TS was performed by PCR amplification using the whole recombinant plasmid pET15b carrying gene coding for the bifunctional P. falciparum DHFR-TS (3D7) as a template, and the primers as listed in Table 2. The resulting truncated mutants, i.e., pf DHFR-TSΔ229-265, pf DHFR-TSΔ229-271, pf DHFR-TSΔ229-274, pf DHFR-TSΔ229-275, pf DHFR-TSΔ229-276, and pf DHFR-TSΔ229-277, were used to co-transform pAC-28 plasmid in the complementation study.

Genetic complementation studies

Overnight culture of the co-transformants was streaked on a minimal agar plate [24] containing 100 μg/ml ampicillin, 30 μg/ml kanamycin, and 0.025 mM IPTG without thymidine supplementation. The plates were incubated at 37°C for 48 hours. Colonies appearing on this plate were considered to have positive genetic complementation, and were selected for subsequent characterization and verification of the expressed enzymes.

Expression and purification of the expressed enzymes

An overnight culture of E. coli χ2913 harbouring two plasmids, i.e., pAC-pf DHFR and truncated pET-pf JRTS with different lengths of truncated JR, was inoculated at 1% inoculum in LB containing 100 μg/ml of ampicillin, 30 μg/ml kanamycin. The bacteria were grown at 37°C until the OD600 of the cell suspension reached ~0.5-0.6, and isopropyl β-D thiogalactopyranoside (IPTG) was added at a final concentration of 0.025 mM. The culture was allowed to grow with shaking at 20°C for 20 hours. The cells were harvested by centrifugation at 6,500 g for 10 min at 4°C, washed once with 250 ml cold phosphate buffered saline, pH 7.4, resuspended in buffer A (20 mM potassium phosphate buffer, pH 7.0, 0.1 mM EDTA, 10 mM DTT, 20% glycerol) containing 0.2 M KCl, and passed through a French Pressure Cell (American Instruments Co Inc, USA) at 12,000 psi three times. After centrifugation at 20,000 g for 1 hour at 4°C, the clear supernatant of the crude sample was circulated at a flow rate of ~0.5 ml/min in a methotrexate-sepharose CL-6B column (1.5 × 5.0 cm) pre-equilibrated with buffer A containing 0.2 M KCl. After overnight circulation, the column was washed with 30 ml of buffer A containing 0.75 M KCl, followed by 20 ml of buffer A containing 0.2 M KCl. The column was then washed with 30 ml of elution buffer (50 mM TES pH 7.8, 0.1 mM EDTA, 10 mM DTT, 20% glycerol, 50 mM KCl) containing 4 mM H2folate to elute DHFR. Fractions of 1 ml were collected. Active fractions with DHFR activity were pooled, concentrated, and H2folate in the pooled fraction was removed by passing the pooled fraction through a pre-packed NAP-25 column (Pharmacia) pre-equilibrated with buffer A.

Enzyme assays and protein analysis

The activity of DHFR was determined spectrophotometrically by monitoring the rate of decrease in absorbance at 340 nm [12, 25]. The standard DHFR assay (1 ml) in a 1-cm path-length cuvette was composed of 100 μM H2folate, 100 μM NADPH, 50 mM TES, pH 7.0, 75 mM β-mercaptoethanol, 1 mg/ml bovine serum albumin, and ~0.01 units of enzyme. The reaction was initiated with H2folate. One unit of DHFR activity is defined as the amount of enzyme that produces 1 μmole of product per minute at 25°C.

The activity of TS was determined by monitoring the increase of absorbance at 340 nm due to the formation of H2folate at 25°C [26]. The reaction (1 ml) in 1-cm path-length cuvette was composed of 50 mM TES, pH 7.4, 25 mM MgCl2, 1 mM EDTA, 6.5 mM HCHO, 75 mM β-mercaptoethanol, 100 μM (6R) CH2H4folate, 125 μM dUMP and the enzyme. The reaction components, except for dUMP, were incubated at 25°C for at least 5 min to obtain the baseline prior to initiation the reaction with dUMP. One unit of TS activity is defined as the amount of enzyme that produces 1 nmole of product per minute at 25°C. The activities of the expressed enzymes were reported as mean ± standard deviation.

[3H]-FdUMP binding assay

The ability of the pf JRTS mutants with truncated JR to form covalent complex with [3H]-FdUMP and CH2H4folate was investigated by incubating the mutant proteins with 0.5 μM [3H]-FdUMP (19.3 Ci/mmol), 0.1 mM CH2H4folate, and 6.5 mM formaldehyde in 50 mM TES pH 7.4, 25 mM MgCl2, 1 mM EDTA, and 75 mM β-mercaptoethanol for 15 min at room temperature. The reaction was then electrophoresed on 12.5% SDS-PAGE. After Coomassie-Blue staining and destaining, the gel was soaked with autoradiography enhancer (EN3HANCE™, New England Nuclear) with gentle shaking for 30 min at room temperature. This was followed by washing the gel with cold water and drying the gel on a piece of filter paper under vacuum at 80°C for 30 min. The dried gel was then exposed on AGFA X-ray film at -80°C with intensifying screens for three to five days before development of the X-ray film.

Bacterial two-hybrid system

Interactions between pf DHFR domain and pf TS domain including those pf TS mutants with truncated JR were investigated using an E. coli two-hybrid system (Stratagene Inc) [27, 28]. The sequence coding for pf DHFR domain was cloned into pBT (bait) vector to yield pBT-pf DHFR, whereas the pf JRTS was cloned into pTRG (target) vector to yield the pTRG-pf JRTS plasmid. The two plasmids were co-transformed into BacterioMatch two-hybrid system reporter strain E. coli XL1-blue MRF’. Positive interaction is indicated by the ability of the bacteria to grow on LB agar plate supplemented with 250 μg/ml carbenicillin, 15 μg/ml tetracycline, 34 μg/ml chloramphenical, and 50 μg/ml kanamycin (LB-CTCK).

Results

Construction of pf JRTS and pf DHFR-TS mutants and growth complementation studies

Unlike the DHFR domain of the bifunctional pf DHFR-TS, which can be heterologously expressed to yield the catalytically active form of enzyme [2932], all attempts to express the catalytically active domain of pf TS have failed. Evidence from deletion of pf DHFR-TS suggested that the amino terminus of the pf DHFR domain is important for the function of the pf TS domain, and interactions between the pf DHFR and pf TS domains are important [18]. To address the important function of JR, mutant constructs of the pf JRTS domain with various lengths of JR sequences were constructed and co-transformed with plasmid expressing the catalytically active pf DHFR domain (pAC-pf DHFR) in TS-deficient E. coli strain χ2913recA(DE3). Successful expression of catalytically active pf TS was monitored by the ability of the co-transformed bacteria to complement growth upon plating on minimum agar plate and the detectable TS activity in the crude extract of the cells.

Figure 1 illustrates the constructs of pf JRTS mutants containing varying lengths of JR attached to the C-terminus of the pf DHFR domain (Asn231). The mutant with the longest JR (pET-pf JRTS232-235) had only four amino acids of the JR (Lys232-Asn235) deleted, while mutants with the shortest JR (pET-pf JRTS232-299) had 68 residues (Lys232-Lys299) removed. A similar approach was undertaken to construct bifunctional pf DHFR-TS deletion mutants of which the JR sequence was shortened to compare the effects of JR deletion with the truncated mutants of pf JRTS constructs. The bifunctional pf DHFR-TS deletion mutants being constructed include pET-pf DHFR-TS229-265, pET-pf DHFR-TS229-271, pET-pf DHFR-TS229-274, pET-pf DHFR-TS229-275, pET-pf DHFR-TS229-276, and pET-pf DHFR-TS229-277 (Figure 2). Figure 3 shows the 89 amino acids of P. falciparum JR sequence and indicates the positions of amino acids that were chosen to prepare truncated and deletion mutants. Results from growth complementation monitored after incubation of the plates overnight at 37°C revealed that pET-pf JRTS232-235, pET-pf JRTS232-251, pET-pf JRTS232-265, pET-pf JRTS232-271, pET-pf JRTS232-274, and pET-pf JRTS232-276 with corresponding JR length of 85, 69, 55, 49, 46, 44 amino acid residues, respectively, could grow on minimum media (Figure 4A, lanes 2–7), while pET-pf JRTS232-277 and pET-pf JRTS232-299 which had the JR length of 43 and 21 residues, respectively, did not show growth complementation (Figure 4A, lanes 8–9). The results suggest that the length of JR was important for the proper folding of the TS domain and hence affected its function. The data revealed that at least 44 residues (the mutant pET-pf JRTS232-276) were required in the case of JR of P. falciparum in order for the pf TS domain to function properly.
https://static-content.springer.com/image/art%3A10.1186%2F1475-2875-12-91/MediaObjects/12936_2012_Article_2720_Fig1_HTML.jpg
Figure 1

Schematic diagram representing full-length pf DHFR-TS, pf DHFR domain, and pf TS domains with truncated junction region (JR). Gene encoding amino acid residues 1–228 of pf DHFR domain was cloned into pAC28 expression vector, whereas gene fragments encoding the pf TS domain with different lengths of JR that are attached to the N-terminus (amino acid residue 320) of pf TS were cloned into the pET15b expression vector. The numbers of amino acid are shown above the gene and the names of the mutants are indicated at the right.

https://static-content.springer.com/image/art%3A10.1186%2F1475-2875-12-91/MediaObjects/12936_2012_Article_2720_Fig2_HTML.jpg
Figure 2

Schematic diagram representing full-length and truncated pf DHFR-TS. Constructs of pf DHFR domain containing amino acids 1–228 followed by truncated JR sequences of different lengths linked to the N-terminus of the pf TS domain were cloned into the pET15b expression vector. The numbers of amino acid are shown above the gene and the names of the mutants are indicated.

https://static-content.springer.com/image/art%3A10.1186%2F1475-2875-12-91/MediaObjects/12936_2012_Article_2720_Fig3_HTML.jpg
Figure 3

Full-length sequence of Plasmodium falciparum JR and the sequences of truncated pf JRTS mutants. The 89 amino acids of the full-length sequence of P. falciparum JR are shown, with amino acid numbers in relation to the full-length bifunctional pf DHFR-TS indicated above the sequence. Arrows indicate the amino acids corresponding to the first amino acid of the truncated pf JRTS constructs. The region where the α-helix is located is marked in the box.

https://static-content.springer.com/image/art%3A10.1186%2F1475-2875-12-91/MediaObjects/12936_2012_Article_2720_Fig4_HTML.jpg
Figure 4

Growth complementation of TS-deficient Escherichia coli cells harbouring. (A) pAC-pfDHFR co-transformed with pET-pfJRTS containing truncated JR. (B) pAC28 co-transformed with pET-pfDHFR-TS with truncated JR. Cells from overnight culture were streaked on Luria-Bertani (LB), minimum media (MM), and minimum media supplemented with 0.025 mM IPTG (MM + IPTG). pET-pfDHFR-TS (3D7) was used as a controlled plasmid.

As with the result for the construct pf JRTS TSΔ229-277, TS-deficient E. coli strain χ2913 recA(DE3) transformed with pET-pf DHFR-TS229-277and pAC-28 could not grow on a minimum agar plate (Figure 4B, lane 7). Therefore, pf DHFR-TS mutants with a longer JR sequence, i.e. pET-pf DHFR-TS229-265, pET-pf DHFR-TS229-271, pET-pf DHFR-TS229-274, pET-pf DHFR-TS229-275, and pET-pf DHFR-TS229-276, were constructed and tested for growth complementation. Complementation studies revealed that the constructs pET-pf DHFR-TS229-265, pET-pf DHFR-TS229-271, and pET-pf DHFR-TS229-274 were able to grow on both LB agar and minimum agar supplemented with 0.025 mM IPTG (Figure 4B, lanes 2–4), whereas the construct pET-pf DHFR-TS229-275 and pET-pf DHFR-TS229-276 failed to show complementation (Figure 4B, lanes 5–6). The results using deletion mutants of bifunctional pf DHFR-TS are in good agreement with those from co-transformation of plasmids encoding pf JRTS with varying lengths of JR and plasmid expressing catalytically active pf DHFR.

[3H]-FdUMP binding studies of pf JRTS and pf DHFR-TS mutant constructs expressing pf TS

[3H]-FdUMP binding studies were carried out to monitor the expression of catalytically active pf TS from truncated pf JRTS mutants and the pf DHFR-TS deletion mutants found to show growth complementation on minimum media. Crude extracts from E. coli χ2913 co-transformed with plasmid expressing pf DHFR and mutant pf JRTSs with varying length of JR were subjected to SDS-PAGE (Figure 5A(I) and B(I)) and the gel was exposed to X-ray film (Figure 5A(II) and B(II)). In agreement with the results from genetic complementation results, co-transformation of pAC-pf DHFR and pET-pf JRTS232-235, pET-pf JRTS232-251, pET-pf JRTS232-265, pET-pf JRTS232-271, pET-pf JRTS232-274 and pET-pf JRTS232-276 formed [3H]-FdUMP-enzyme complexes which could be visualized on X-ray film as a band according to the size predicted from that of pf JRTS (Figure 5B, lanes 2–7). Co-transformation of pAC-pf DHFR and pf JRTS232-277 and pf JRTS232-299, however, showed relatively weak signal from [3H]-FdUMP-enzyme complexes (Figure 5B, lanes 8–9).
https://static-content.springer.com/image/art%3A10.1186%2F1475-2875-12-91/MediaObjects/12936_2012_Article_2720_Fig5_HTML.jpg
Figure 5

[ 3 H]-FdUMP binding of crude extracts and partially purified proteins. Crude extracts and partially purified proteins from plasmids encoding pfDHFR co-transformed with pfJRTS mutants with truncated JR (panels A and B, respectively), and plasmids encoding pAC28 co-transformed with pfDHFR-TS with truncated JR (panel C and D, respectively) were labeled with [3H]-FdUMP. For panels A and B: lane 1, pf DHFR-TS (3D7); lane 2, pf JRTS232-235 co-expressed with pAC28-pf DHFR; lane 3, pf JRTS232-251 co-expressed with pAC28-pf DHFR; lane 4, pf JRTS232-265 co-expressed with pAC28-pf DHFR; lane 5, pf JRTS232-271 co-expressed with pAC28-pf DHFR; lane 6, pf JRTS232-274co-expressed with pAC28-pf DHFR; lane 7, pf JRTS232-276 co-expressed with pAC28-pf DHFR; lane 8, pf JRTS232-277 co-expressed with pAC28-pf DHFR; lane 9, pf JRTS232-299 co-expressed with pAC28-pf DHFR. For panels C and D: lane 1, pf DHFR-TS (3D7); lane 2, pf DHFR-TS229-265; lane 3, pf DHFR-TS229-271; lane 4, pf DHFR-TS229-274; lane 5, pf DHFR-TS229-275; lane 6, pf DHFR-TS229-276; lane 7, pf DHFR-TS229-277993. M is the molecular weight standard markers. (I) Coomassie blue stained SDS-PAGE, (II) autoradiogram of the SDS gel.

To investigate the role of JR in bifunctional pf DHFR-TS, formation of [3H]-FdUMP-enzyme complexes were monitored from the extracts of E. coli cells co-transformed with pAC28 plasmid and pET-pf DHFR-TS229-265, pET-pf DHFR-TS229-271, pET-pf DHFR-TS229-274, pET-pf DHFR-TS229-275, and pET-pf DHFR-TS229-276 (Figure 5C and 5D). The results showed that both crude extracts and partially purified proteins of these constructs could form complexes with [3H]-FdUMP, though growth complementation could not be observed from pET-pf DHFR-TS229-275, pET-pf DHFR-TS229-276, and pET-pf DHFR-TS229-277 (Figure 5D, lanes 5–7).

Purification and characterization of the expressed enzymes

Crude extracts of the transformed TS-deficient E. coli that were both positive and negative from the growth complementation studies were assayed for DHFR and TS activities. Extracts that were positive were passed through a MTX-affinity column for purification of the pf DHFR domain [32]. The results from enzyme assays revealed that the specific activity of pf DHFR from all the co-transformants were not significantly different among the crude extracts (average 36.2 ± 3.1 nmole/min/mg), but the activity was only about half of that observed from the crude extract of the bifunctional pf DHFR-TS (Table 3). The specific activities of the partially purified pf DHFR upon affinity purification were 1,371 ± 208 nmole/min/mg (Table 3), about 3 times lower than that obtained from the purified pf DHFR-TS. Interestingly, the TS activities of the purified enzymes from the truncated pf JRTS mutants are in most cases 1–2 times higher than that from the purified pf DHFR-TS. The activity of pf TS was found to co-elute with that of pf DHFR, suggesting that the expressed pf TS domain was somehow associated with the pf DHFR domain. As indicated in Table 3, the TS activity of the pf JRTS mutants was found to decrease upon shortening the length of JR in the construct.
Table 3

DHFR and TS activities in crude extracts and purified enzymes from TS-deficient Escherichia coli χ2913 harbouring pAC- pf DHFR and pET- pf JRTS with different lengths of JR

Specific activity

Plasmid

Crude extract*

Purified enzyme**

(nmole/min/mg)

(nmole/min/mg)

DHFR

TS

DHFR

TS

1. pET-pf DHFRTS (3D7)

70.3 ± 3.6

3.7 ± 0.4

5331.9 ± 113.8

99.0 ± 1.0

2. pAC-pf DHFR + pET-pf JRTSΔ232-235

39.5 ± 5.8

2.6 ± 0.2

1511.1 ± 227.5

164.1 ± 22.6

3. pAC-pf DHFR + pET-pf JRTSΔ232-251

34.2 ± 5.8

2.1 ± 0.4

1394.5 ± 275.7

134.4 ± 8.9

4. pAC-pf DHFR + pET-pf JRTSΔ232-265

37.8 ± 5.3

3.8 ± 0.5

1668.4 ± 234.7

132.0 ± 7.4

5. pAC-pf DHFR + pET-pf JRTSΔ232-271

39.9 ± 7.3

3.9 ± 0.7

1601.7 ± 206.1

107.9 ± 23.3

6. pAC-pf DHFR + pET-pf JRTSΔ232-274

38.3 ± 5.6

1.5 ± 0.3

1328.8 ± 231.7

70.1 ± 0.2

7. pAC-pf DHFR + pET-pf JRTSΔ232-276

34.2 ± 9.1

1.1 ± 0.1

1140.1 ± 137.8

44.2 ± 7.5

8. pAC-pf DHFR + pET-pf JRTSΔ232-277

31.0 ± 8.1

ND

1136.5 ± 132.0

ND

9. pAC-pf DHFR + pETpf JRTSΔ232-279

34.9 ± 7.2

ND

1193.6 ± 111.8

ND

10. pAC-28 + pET-15b

7.7 ± 0.4

ND

-

-

* Average values from three independent experiments.

**Average values from two independent experiments.

ND: not detectable.

The importance of the length of the JR sequence on the activity of pf TS was also investigated using the bifunctional pf DHFR-TS. Site-directed mutagenesis of the bifunctional pf DHFR-TS was performed to yield mutants containing the same lengths of JR as for the pf JRTS mutant constructs described above. These mutants include pET-pf DHFR-TS229-265, pET-pf DHFR-TS229-271, pET-pf DHFR-TS229-274, pET-pf DHFR-TS229-275, pET-pf DHFR-TS229-276, and pET-pf DHFR-TS229-277. Table 4 summarizes the pf DHFR and pf TS activities of the bifunctional DHFR-TS and the bifunctional mutants from the crude extracts and upon partial purification. In agreement with the growth complementation experiments, no pf TS activity was detected from the crude extracts and partial purification of pET-pf DHFR-TS229-275, pET-pf DHFR-TS229-276, and pET-pf DHFR-TS229-277 mutants. However, the activities of the pf DHFR domain of these mutants remained active, though they were found to gradually decrease upon shortening the length of the JR sequence.
Table 4

DHFR and TS activities in crude extracts and purified enzymes from TS-deficient Escherichia coli χ2913 harbouring pET- pf DHFR-TS and pET- pf DHFR-TS constructs with different lengths of JR

Specific activity

Plasmid

Crude extract*

Purified enzyme**

(nmole/min/mg)

(nmole/min/mg)

DHFR

TS

DHFR

TS

1. pET-pf DHFR-TS (3D7)

70.3 ± 3.6

3.7 ± 0.4

5331.9 ± 113.8

99.0 ± 1.0

2. pET-pf DHFR-TSΔ229-265

64.7 ± 5.8

1.1 ± 0.3

4583.2 ± 228.9

44.8 ± 1.9

3. pET-pf DHFR-TSΔ229-271

75.5 ± 12.4

1.0 ± 0.3

3844.6 ± 130.6

40.9 ± 5.9

4. pET-pf DHFR-TSΔ229-274

74.4 ± 18.5

0.9 ± 0.2

3487.8 ± 213.2

35.8 ± 2.4

5. pET-pf DHFR-TSΔ229-275

66.7 ± 7.3

ND

4719.3 ± 391.3

ND

6. pET-pf DHFR-TSΔ229-276

83.9 ± 1.0

ND

3357.8 ± 443.3

ND

7. pET-pf DHFR-TSΔ229-277

82.1 ± 3.0

ND

3137.8 ± 210.3

ND

8. pET-15b

3.1 ± 0.1

ND

-

-

* Average values from three independent experiments.

** Average values from two independent experiments.

ND: not detectable.

Demonstration of pf DHFR-TS domain-domain interaction by Escherichia coli two-hybrid system

The interaction between the pf DHFR domain and pf JRTS was demonstrated using E. coli BacterioMatch™ two-hybrid system (Strategene). The pf DHFR domain was cloned into Not I-BamH I sites of a pBT bait plasmid, resulting in a pBT-pf DHFR plasmid, which contains the pfdhfr gene fused at the end of the bacteriophage λcI gene. The pf JRTS domain was cloned into BamH I-Xho I sites of the pTRG target plasmid, resulting in constructs that express truncated pf JRTS domains fused with the α-subunit of RNA polymerase. If the pf JRTS domain could interact with the pf DHFR domain, then this would stabilize the binding of RNA polymerase located close to the promoter and activate the transcription of the AmpR reporter gene. As a consequence, the transformed reporter strain (E. coli XL1-blue MRF’) showed growth on Luria-Bertani agar containing carbenicillin, tetracycline, chloramphenical and kanamycin (LB-CTCK).

The interaction between the DHFR monomer and the donated helix within the JR sequence has earlier been noted from the structures of the bifunctional DHFR-TS enzymes of C. hominis and P. falciparum[17, 33]. An interaction of the pf DHFR and pf JRTS domains was demonstrated using the E. coli two-hybrid system [27, 28, 34]. The E. coli reporter strain co-transformed with plasmids pBT-pf DHFR and pTRG-pf JRTS (with full-length JR sequence) can grow on a LB-CTCK agar plate (Figure 6). The data is in agreement with the complementation results and results from [3H]-FdUMP binding studies supporting the importance of JR on the folding of the pf TS domain.
https://static-content.springer.com/image/art%3A10.1186%2F1475-2875-12-91/MediaObjects/12936_2012_Article_2720_Fig6_HTML.jpg
Figure 6

Escherichia coli two-hybrid showing interaction between pf DHFR and pf TS domains. Escherichia coli BacterioMatch™ two-hybrid system (Strategene) was employed for the study of the domain-domain interaction between P. falciparum DHFR and TS domains. The gene coding for pf DHFR was cloned into the bait plasmid pBT, whereas the gene for pf JRTS was cloned into the target plasmid pTRG. The two recombinant plasmids were transformed into the E. coli XL1-blue MRF’ reporter strain. Positive control is E. coli XL1-blue MRF’ co-transformed with pBT-LDF2 and pTRG-Gal11p provided by the manufacturer. Negative control is E. coli XL1-blue MRF’. Agar plate on the left is LB-kanamycin (LB-K) and that on the right is LB- carbenicillin, tetracycline, chloramphenical and kanamycin (LB-CTCK).

Discussion

The JR represents a junctional region linked between the DHFR and the TS domain of parasitic protozoa. This region has been proposed as potential target for drug development in many parasitic protozoa. Indeed, this region in C. hominis from one monomer was reported to make extension contacts with the DHFR active site of the other monomer [17]. In P. falciparum, the amino acid residues Asp283-Asn296 of JR are strongly predicted to be involved in domain-domain interaction. Unfortunately, the major portions of JR (Lys232-Asn280) were not seen in the crystal structure previously reported [33]. Therefore, it remains unclear whether each DHFR domain of P. falciparum is linked to the TS domain as seen in C. hominis or there is a domain swapping assembly. The role of JR was characterized with respect to interdomain interaction.

A series of truncated mutants of pf JRTS were constructed containing varying lengths of JR and their interactions with the active pf DHFR domain were examined. By employing TS-deficient E. coli χ2913 and monitoring its growth complementation in minimum media without thymidine supplementation, the study showed that the pf JRTS construct with the shortest length of JR that could still show growth complementation in TS-deficient E. coli χ2913 was pf JRTS232-276. The specific activity of DHFR determined for the crude extract of the monofunctional pf DHFR upon co-expression with pf JRTS232-276 was 34.2 ± 9.1 nmole/min/mg, a value which was about half that obtained from the bifunctional pf DHFR-TS (70.3 ± 3.6 nmole/min/mg), but was about the same level for all truncated pf JRTS mutants. However, the specificity of TS of this truncated construct was only 1.1 ± 0.1 nmole/min/mg (Table 3), which is about 29% of the wild-type enzyme (3.7 ± 0.4 nmole/min/mg). It is noteworthy that the DHFR specific activities among the co-transformants investigated were comparable whereas the TS specific activities were dramatically reduced upon shortening of the JR sequence. The pf DHFR and pf JRTS domains could be co-purified by using a MTX-affinity column, suggesting that the pf DHFR and pf TS domains interacted with each other because methotrexate binds only to the pf DHFR domain. For the co-transformants that lose the pf TS activity including pf JRTS232-277 and pf JRTS232-299, the constructs still expressed active pf DHFR (Table 3). The expression of catalytically active pf TS upon cotransformation with pf DHFR plasmid was further confirmed by showing a positive autoradiogram of covalent complex formed as a result of [3H]-FdUMP bound to the expressed pf TS from the pf JRTS232-276 mutant construct.

These results agree well with the previous studies, suggesting that the pf DHFR domain is essential for pf TS to be active [18, 35]. However, one interesting piece of data from this laboratory showed that co-expression of the death mutant pf DHFR (Ser108 to Trp108 mutation) [36] and pf JRTS232-235 or P. vivax DHFR with pf JRTS232-235 could not confer expression of catalytically active pf TS (data not shown). This finding suggests that not only minimal length of JR is required but active pf DHFR domain is also important for the pf TS domain to be active. Although endogenous DHFR from an E. coli host exists, the enzyme could not promote the growth of TS-deficient E. coli. It is possible that amino acids within the pf DHFR domain are critically necessary to stabilize the DHFR tertiary structure which could indirectly influence the correct folding and hence the activity of the pf TS domain.

The domain-domain interaction of the bifunctional pf DHFR-TS was further demonstrated using an E. coli two hybrid system and the results obtained were consistent with other experiments. The pBT-pf DHFR and pTRG-pf JRTS co-transformant showed interaction and turned on the AmpR gene, allowing the growth of E. coli XL1-blue MRF’. The results suggest that the minimal length of JR which could allow expression of the catalytically active pf TS was 44 amino acids, approximately half the full length of JR of the P. falciparum DHFR-TS.

The importance of the length of JR was investigated by the ability to complement the growth of TS-deficient E. coli in the absence of thymine of co-transformed plasmids harbouring the genes for pf DHFR and truncated pf JRTS compared to plasmid harbouring the gene for the bifunctional pf DHFR-TS. Complementation experiments support the conclusion that the length of JR sequence is crucial. The finding that positive complementation was still observed from the construct of truncated bifunctional pf DHFR-TS229-274 which possesses two more amino acid residues than the case of monofunctional pf JRTS232-276 could be due to the more complex structure of the bifunctional protein as compared to the monofunctional enzymes resulting from the interaction, or associated with the sensitivity of the complementation assay system. To further address this discrepancy, a more sensitive [3H]-FdUMP binding assay method was used to confirm that pf DHFR-TS229-276 is the construct with the shortest length of JR that could still express active pf TS. The result was in good agreement with the results from complementation studies using monofunctional pf JRTS229-276. The fact that the bifunctional mutant failed to show complemention in TS-deficient E. coli but could not detect the activity of pf TS by in vitro enzymatic assay could be due to the insufficient expression of protein in combination with the sensitivity of the complemention method, since a minimum TS activity of ~1-5 nmole/min/mg is necessary for complementation to be observed in E. coli χ2913 [37]. It should also be noted that the low expression observed in the truncated bifunctional pf DHFR-TS was consistent with a previous mutation study which proposed that the significant intracellular proteolysis activity associated with the α-helix structure in this region could be attributed to the low expression of the mutant proteins [38].

The present results clearly demonstrated that shortening the JR sequence in the pf DHFR-TS could affect the activity of both pf TS and pf DHFR. Contrary to that observed in T. gondii and C. hominis which have longer JR sequences, mutations of the JR sequence were reported to affect only the activity of DHFR but not the activity of TS [39, 40]. This and other data support the conclusion that the length of JR sequence is necessary for the activity of both pf DHFR and pf TS domains, and hence highlights the importance of the JR sequence in P. falciparum bifunctional DHFR-TS.

It was not so surprising that the constructs pf JRTS232-277 and pf DHFR-TS229-277 showed no expression of catalytically active pf TS, despite the fact that the constructs contain a sequence that encompasses Asp283-Asn296, the region previously predicted to form α-helix and responsible for electrostatic interaction between the negatively charge residues and positive charge of the pf DHFR and pf TS from different domains [33]. A number of possible explanations could be as follows: (i) the length of JR in the constructs is too short, and this could affect the formation of a stable helix and consequently disturb the interaction with pf DHFR and interfere with the proper formation of pf TS conformation; (ii) too short a JR sequence could affect the structure which could result in a steric constraint or functional infringement of one domain upon the other; (iii) the existence of translational autoregulation could block translation of mRNA coding for bifunctional enzyme from binding to the DHFR domain of the protein [41]; and, (iv) the mutation could cause exposure of some parts of the enzyme which are sensitive to proteolysis [38]. Therefore, too short a JR sequence could neither support interaction between pf DHFR and pf TS domains nor contribute to proper folding of the pf DHFR-TS bifunctional protein.

Conclusions

The data presented in this study show that: a) the presence of an active pf DHFR domain and the appropriate length of JR are critical for pf TS to fold correctly to be catalytically active; and, b) deletion of JR affects both the activities of the pf TS and the pf DHFR domain of the bifunctional pf DHFR-TS. From this study, the JR of P. falciparum has a unique role which is different from other long linker parasitic protozoa. The data described here could be useful for the development of compounds that bind to the JR and interfere with the dimerization of the pf TS subdomains. These studies could potentially lead to novel means of development of inhibitors targeting the JR sequence of the parasite.

Abbreviations

DHFR-TS: 

Dihydrofolate reductase-thymidylate synthase

SHMT: 

Serine hydroxymethyltransferase

dTMP: 

2-deoxythymidine 5-monophosphate

[3H]-FdUMP: 

Tritiated-5-fluoro-2-deoxyuridine 5-monophosphate

JR: 

Junctional region

MM: 

Minimal media

MTX: 

Methotrexate

Declarations

Acknowledgements

The authors are grateful to Drs. Michael A. Allen, Alfredo Villarroel and Alejandro Sáiz for critical review of the manuscript. This work was supported in part by the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) and the Office of the Higher Education Commission and Mahidol University under the National Research Universities Initiative to WS. NC is a recipient of a grant under the programme Strategic Scholarships for Frontier Research Network for the Joint PhD Program Thai Doctoral degree from the Commission on Higher Education, Thailand.

Authors’ Affiliations

(1)
Department of Biochemistry, Faculty of Science, Mahidol University

References

  1. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW: The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis. 2004, 4: 327-336. 10.1016/S1473-3099(04)01043-6.PubMed CentralView ArticlePubMed
  2. Bouma MJ, Sondorp HE, van der Kaay HJ: Climate change and periodic epidemic malaria. Lancet. 1994, 343: 1440-View ArticlePubMed
  3. Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ: Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci USA. 1988, 85: 9109-9113. 10.1073/pnas.85.23.9109.PubMed CentralView ArticlePubMed
  4. Foote SJ, Galatis D, Cowman AF: Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc Natl Acad Sci USA. 1990, 87: 3014-3017. 10.1073/pnas.87.8.3014.PubMed CentralView ArticlePubMed
  5. Peterson DS, Walliker D, Wellems TE: Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA. 1988, 85: 9114-9118. 10.1073/pnas.85.23.9114.PubMed CentralView ArticlePubMed
  6. Peterson DS, Milhous WK, Wellems TE: Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci USA. 1990, 87: 3018-3022. 10.1073/pnas.87.8.3018.PubMed CentralView ArticlePubMed
  7. Hyde JE: Point mutations and pyrimethamine resistance in Plasmodium falciparum. Parasitol Today. 1989, 5: 252-255. 10.1016/0169-4758(89)90257-3.View ArticlePubMed
  8. Zolg JW, Plitt JR, Chen GX, Palmer S: Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum. Mol Biochem Parasitol. 1989, 36: 253-262. 10.1016/0166-6851(89)90173-4.View ArticlePubMed
  9. Ivanetich KM, Santi DV: Bifunctional thymidylate synthase-dihydrofolate reductase in protozoa. FASEB J. 1990, 4: 1591-1597.PubMed
  10. Bzik DJ, Li WB, Horii T, Inselburg J: Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Proc Natl Acad Sci USA. 1987, 84: 8360-8364. 10.1073/pnas.84.23.8360.PubMed CentralView ArticlePubMed
  11. Hyde JE: The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites. Pharmacol Ther. 1990, 48: 45-59. 10.1016/0163-7258(90)90017-V.View ArticlePubMed
  12. Meek TD, Garvey EP, Santi DV: Purification and characterization of the bifunctional thymidylate synthetase-dihydrofolate reductase from methotrexate-resistant Leishmania tropica. Biochemistry. 1985, 24: 678-686. 10.1021/bi00324a021.View ArticlePubMed
  13. Trujillo M, Donald RG, Roos DS, Greene PJ, Santi DV: Heterologous expression and characterization of the bifunctional dihydrofolate reductase-thymidylate synthase enzyme of Toxoplasma gondii. Biochemistry. 1996, 35: 6366-6374. 10.1021/bi952923q.View ArticlePubMed
  14. Elcock AH, Potter MJ, Matthews DA, Knighton DR, McCammon JA: Electrostatic channeling in the bifunctional enzyme dihydrofolate reductase-thymidylate synthase. J Mol Biol. 1996, 262: 370-374. 10.1006/jmbi.1996.0520.View ArticlePubMed
  15. Stroud RM: An electrostatic highway. Nat Struct Biol. 1994, 1: 131-134. 10.1038/nsb0394-131.View ArticlePubMed
  16. Knighton DR, Kan CC, Howland E, Janson CA, Hostomska Z, Welsh KM, Matthews DA: Structure of and kinetic channelling in bifunctional dihydrofolate reductase-thymidylate synthase. Nat Struct Biol. 1994, 1: 186-194. 10.1038/nsb0394-186.View ArticlePubMed
  17. O’Neil RH, Lilien RH, Donald BR, Stroud RM, Anderson AC: Phylogenetic classification of protozoa based on the structure of the linker domain in the bifunctional enzyme, dihydrofolate reductase-thymidylate synthase. J Biol Chem. 2003, 278: 52980-52987. 10.1074/jbc.M310328200.View ArticlePubMed
  18. Shallom S, Zhang K, Jiang L, Rathod PK: Essential protein-protein interactions between Plasmodium falciparum thymidylate synthase and dihydrofolate reductase domains. J Biol Chem. 1999, 274: 37781-37786. 10.1074/jbc.274.53.37781.PubMed CentralView ArticlePubMed
  19. Futterman S: Enzymatic reduction of folic acid and dihydrofolic acid to tetrahydrofolic acid. J Biol Chem. 1957, 228: 1031-1038.PubMed
  20. Blakley RL: Spectrophotometric studies on the combination of formaldehyde with tetrahydropteroylglutamic acid and other hydropteridines. Biochem J. 1960, 74: 71-82.PubMed CentralView ArticlePubMed
  21. Sirawaraporn W, Sirawaraporn R, Cowman AF, Yuthavong Y, Santi DV: Heterologous expression of active thymidylate synthase-dihydrofolate reductase from Plasmodium falciparum. Biochemistry. 1990, 29: 10779-10785. 10.1021/bi00500a009.View ArticlePubMed
  22. Miyazaki K, Takenouchi M: Creating random mutagenesis libraries using megaprimer PCR of whole plasmid. Biotechniques. 2002, 35: 1033-1034.
  23. Kholod N, Mustelin T: Novel vectors for co-expression of two proteins in E. coli. Biotechniques. 2001, 31: 322-323. 326–328PubMed
  24. Belfort M, Moelleken A, Maley GF, Maley F: Purification and properties of T4 phage thymidylate synthetase produced by the cloned gene in an amplification vector. J Biol Chem. 1983, 258: 2045-2051.PubMed
  25. Hillcoat BL, Nixon PF, Blakley RL: Effect of substrate decomposition on the spectrophotometric assay of dihydrofolate reductase. Anal Biochem. 1967, 21: 178-189. 10.1016/0003-2697(67)90179-0.View ArticlePubMed
  26. Wahba AJ, Friedkin M: Direct spectrophotometric evidence for the oxidation of tetrahydrofolate during the enzymatic synthesis of thymidylate. J Biol Chem. 1961, 236: PC11-PC12.PubMed
  27. Dove SL, Joung JK, Hochschild A: Activation of prokaryotic transcription through arbitrary protein-protein contacts. Nature. 1997, 386: 627-630. 10.1038/386627a0.View ArticlePubMed
  28. Dove SL, Hochschild A: Conversion of the omega subunit of Escherichia coli RNA polymerase into a transcriptional activator or an activation target. Genes Dev. 1998, 12: 745-754. 10.1101/gad.12.5.745.PubMed CentralView ArticlePubMed
  29. Hall SJ, Sims PF, Hyde JE: Functional expression of the dihydrofolate reductase and thymidylate synthetase activities of the human malaria parasite Plasmodium falciparum in Escherichia coli. Mol Biochem Parasitol. 1991, 45: 317-330. 10.1016/0166-6851(91)90100-K.View ArticlePubMed
  30. Sirawaraporn W, Prapunwattana P, Sirawaraporn R, Yuthavong Y, Santi DV: The dihydrofolate reductase domain of Plasmodium falciparum thymidylate synthase-dihydrofolate reductase. Gene synthesis, expression, and anti-folate-resistant mutants. J Biol Chem. 1993, 268: 21637-21644.PubMed
  31. Sano G, Morimatsu K, Horii T: Purification and characterization of dihydrofolate reductase of Plasmodium falciparum expressed by a synthetic gene in Escherichia coli. Mol Biochem Parasitol. 1994, 63: 265-273. 10.1016/0166-6851(94)90062-0.View ArticlePubMed
  32. Hekmat-Nejad M, Lee PC, Rathod PK:Plasmodium falciparum: direct cloning and expression of pyrimethamine-sensitive and pyrimethamine-resistant dihydrofolate reductase domains. Exp Parasitol. 1997, 85: 303-305. 10.1006/expr.1997.4145.View ArticlePubMed
  33. Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S, Vanichtanankul J, Sirawaraporn W, Taylor P, Walkinshaw MD, Yuthavong Y: Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol. 2003, 10: 357-365. 10.1038/nsb921.View ArticlePubMed
  34. Joung JK, Ramm EI, Pabo CO: A bacterial two-hybrid selection system for studying protein-DNA and protein-protein interactions. Proc Natl Acad Sci USA. 2000, 97: 7382-7387. 10.1073/pnas.110149297.PubMed CentralView ArticlePubMed
  35. Wattanarangsan J, Chusacultanachai S, Yuvaniyama J, Kamchonwongpaisan S, Yuthavong Y: Effect of N-terminal truncation of Plasmodium falciparum dihydrofolate reductase on dihydrofolate reductase and thymidylate synthase activity. Mol Biochem Parasitol. 2003, 126: 97-102. 10.1016/S0166-6851(02)00240-2.View ArticlePubMed
  36. Sirawaraporn W, Yongkiettrakul S, Sirawaraporn R, Yuthavong Y, Santi DV:Plasmodium falciparum: asparagine mutant at residue 108 of dihydrofolate reductase is an optimal antifolate-resistant single mutant. Exp Parasitol. 1997, 87: 245-252. 10.1006/expr.1997.4221.View ArticlePubMed
  37. Climie S, Ruiz-Perez L, Gonzalez-Pacanowska D, Prapunwattana P, Cho SW, Stroud R, Santi DV: Saturation site-directed mutagenesis of thymidylate synthase. J Biol Chem. 1990, 265: 18776-18779.PubMed
  38. Dasgupta T, Anderson KS: Probing the role of parasite-specific, distant structural regions on communication and catalysis in the bifunctional thymidylate synthase-dihydrofolate reductase from Plasmodium falciparum. Biochemistry. 2008, 47: 1336-1345. 10.1021/bi701624u.PubMed CentralView ArticlePubMed
  39. Belperron AA, Fox BA, O’Neil RH, Peaslee KA, Horii T, Anderson AC, Bzik DJ:Toxoplasma gondii: generation of novel truncation mutations in the linker domain of dihydrofolate reductase-thymidylate synthase. Exp Parasitol. 2004, 106: 179-182. 10.1016/j.exppara.2004.03.002.View ArticlePubMed
  40. Vargo MA, Martucci WE, Anderson KS: Disruption of the crossover helix impairs dihydrofolate reductase activity in the bifunctional enzyme TS-DHFR from Cryptosporidium hominis. Biochem J. 2009, 417: 757-764. 10.1042/BJ20081247.PubMed CentralView ArticlePubMed
  41. Zhang K, Rathod PK: Divergent regulation of dihydrofolate reductase between malaria parasite and human host. Science. 2002, 296: 545-547. 10.1126/science.1068274.View ArticlePubMed

Copyright

© Chaianantakul et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement